Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "NECA's Long"


2 mentions found


Every year, nearly 10,000 electricians either retire or change careers, but only about 7,000 new ones enter the field. "We're benefitting from a generation that's looking past high school and is not seeing a career going through the traditional four-year college pathway. Contributing to that shift are high school guidance counselors like Steve Schneider, who has advised students for 28 years, currently at Sheboygan South High School in Wisconsin. It offers high school students hands-on training alongside workers from local companies, introducing them to skilled trades and other occupations, which can lead to an apprenticeship after graduation. Among LATTC's 12,000 students, 4,600 are currently enrolled in electrician training, he said, adding that tuition is around $1,000 a year.
Persons: , David Long, They're, Adrian Sauceda, We've, Sauceda, Thayer Long, IEC's Thayer Long, Steve Schneider, Schneider, Kohler, NECA's David Long, Bill Elarton, Selig, Alan Marzullo, Marzullo, NECA's Long Organizations: Bureau of Labor Statistics, BLS, National Electrical Contractors Association, International Brotherhood of Electrical Workers, Independent Electrical Contractors, IEC, Sheboygan South High School, Rockline Industries, Inspire Wisconsin, NECA, Electrical Training Alliance, Department of Labor, Los Angeles Trade, Technical College, Syracuse University's College of Professional Studies, Consortium, Micron Technology, Local, Micron Locations: U.S, Wisconsin, Sheboygan, America, Clay , New York
The company also predicted a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth even as prices remain under pressure. Sales of its best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — came in just below estimates from Cowen analysts. Sales started to pick up in the second half of 2022 and in the fourth quarter grew by 3% at constant currency rates. Of key interest to investors is the experimental cancer drug, datopotamab deruxtecan, being evaluated in a keenly anticipated late-stage trial involving lung cancer patients. Partner Daiichi Sankyo (4568.T) this month said results of that study have been delayed to the second quarter from the first quarter of 2023.
Total: 2